Teva Announces Launch Of Generic Equivalent Of Actonel For Osteoporosis In U.S.

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Monday announced the launch of the generic equivalent to Actonel or risedronate sodium Tablets to treat or prevent osteoporosis in women after menopause. The company will make available 5 mg, 30 mg, and 35 mg in the United States. Teva will be eligible for 180 days of market exclusivity, as it was first to file for the equivalent.

Risedronate sodium tablets are used to increase bone mass and help reduce the chance of having a spinal or non-spinal fracture. It is also used to treat or prevent osteoporosis in either men or women who are taking corticosteroid medicines, and to treat Paget's disease of the bone.

Actonel Tablets were first marketed by Actavis had annual sales of approximately $157 million in the U.S. About 54 million Americans have low bone mass and osteoporosis, a condition that causes the bones to become weak and brittle.